Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 247

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Rivastigmine for Alzheimer's disease

Birks, Jacqueline S, Grimley Evans, John · 2015 · Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Alzheimer's disease is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and lower risk of adverse effects have since been introduced. Rivastigmine has received approval for use in 60 countries including all member states of the European Union and the USA. OBJECTIVES: To determine the clinical efficacy and safety of rivastigmine for patients with dementia of Alzheimer's type. SEARCH METHODS: We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group Specialized Register, on 2 March 2015 using the terms: Rivastigmine OR exelon OR ENA OR "SDZ ENA 713". ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS), numerous trial registries and grey literature sources. SELECTION CRITERIA: We included all unconfounded, double-blind, randomised, controlled trials in which treatment with rivastigmine was administered to patients with dementia of the Alzheimer's type for 12 weeks or more and its effects compared with those of placebo in a parallel group of patients, or where two formulations of rivastigmine were compared. DATA COLLECTION AND ANALYSIS: One review author (JSB) applied the study selection criteria, assessed the quality of studies and extracted data. MAIN RESULTS: A total of 13 trials met the inclusion criteria of the review. The trials had a duration of between 12 and 52 weeks. The older trials tested a capsule form with a dose of up to 12 mg/day. Trials reported since 2007 have tested continuous dose transdermal patch formulations delivering 4.6, 9.5 and 17.7 mg/day.Our main analysis compared the safety and efficacy of rivastigmine 6 to 12 mg/day orally or 9.5 mg/day transdermally with placebo.Seven trials contributed data from 3450 patients to this analysis. Data from another two studies were not included because of a lack of information and methodological concerns. All the included trials were multicentre trials and recruited patients with mild to moderate Alzheimer's disease with a mean age of about 75 years. All had low risk of bias for randomisation and allocation but the risk of bias due to attrition was unclear in four studies, low in one study and high in two studies.After 26 weeks of treatment rivastigmine compared to placebo was associated with better outcomes for cognitive function measured with the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) score (mean difference (MD) -1.79; 95% confidence interval (CI) -2.21 to -1.37, n = 3232, 6 studies) and the Mini-Mental State Examination (MMSE) score (MD 0.74; 95% CI 0.52 to 0.97, n = 3205, 6 studies), activities of daily living (SMD 0.20; 95% CI 0.13 to 0.27, n = 3230, 6 studies) and clinician rated global impression of changes, with a smaller proportion of patients treated with rivastigmine experiencing no change or a deterioration (OR 0.68; 95% CI 0.58 to 0.80, n = 3338, 7 studies).Three studies reported behavioural change, and there were no differences compared to placebo (standardised mean difference (SMD) -0.04; 95% CI -0.14 to 0.06, n = 1529, 3 studies). Only one study measured the impact on caregivers using the Neuropsychiatric Inventory-Caregiver Distress (NPI-D) scale and this found no difference between the groups (MD 0.10; 95% CI -0.91 to 1.11, n = 529, 1 study). Overall, participants who received rivastigmine were about twice as likely to withdraw from the trials (odds ratio (OR) 2.01, 95% CI 1.71 to 2.37, n = 3569, 7 studies) or to experience an adverse event during the trials (OR 2.16, 95% CI 1.82 to 2.57, n = 3587, 7 studies). AUTHORS' CONCLUSIONS: Rivastigmine (6 to 12 mg daily orally or 9.5 mg daily transdermally) appears to be beneficial for people with mild to moderate Alzheimer's disease. In comparisons with placebo, better outcomes were observed for rate of decline of cognitive function and activities of daily living, although the effects were small and of uncertain clinical importance. There was also a benefit from rivastigmine on the outcome of clinician's global assessment. There were no differences between the rivastigmine group and placebo group in behavioural change or impact on carers. At these doses the transdermal patch may have fewer side effects than the capsules but has comparable efficacy. The quality of evidence is only moderate for all of the outcomes reviewed because of a risk of bias due to dropou

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd001191.pub3

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 159

  1. Agid, 1998, Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type, Current Therapeutic Research, 59, 837, 10.1016/S0011-393X(98)85048-0 · DOI
  2. Anand, 1996, Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's Disease: an overview, Journal of Drug Development and Clinical Practice, 8, 109
  3. Anand, 1996, Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's Disease: an overview, Journal of Drug Development and Clinical Practice, 8, 109
  4. Forette, 1999, A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®), European Journal of Neurology, 6, 423, 10.1046/j.1468-1331.1999.640423.x · DOI
  5. Anand, 2001, Effects of Alzheimer's disease severity on activities of daily living with long-term rivastigmine treatment, Journal of the American Geriatrics Society, 49, S151
  6. Burns, 2004, Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease, International Journal of Geriatric Psychiatry, 19, 243, 10.1002/gps.1058 · DOI
  7. Erkinjuntti, 2003, Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains, International Journal of Clinical Practice, 57, 756, 10.1111/j.1742-1241.2003.tb10609.x · DOI
  8. Erkinjuntti, 2002, Rivastigmine in patients with Alzheimer's disease and concurrent hypertension, International Journal of Clinical Practice, 56, 791, 10.1111/j.1742-1241.2002.tb11377.x · DOI
  9. Farlow, 2003, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Archives of Neurology, 60, 843, 10.1001/archneur.60.6.843 · DOI
  10. Hebert, 1999, [Alzheimer disease: efficacy and tolerance of rivastigmine], Presse Medicale, 28, 1757
  11. Roesler, 1998, Effect of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease, Behavioural-Neurology, 11, 211, 10.1155/1999/168023 · DOI
  12. Rösler, 1997, A double-blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT), Pharmacopsychiatry, 30, 212
  13. Rösler, 1998, Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease, Behavioural-Neurology, 11, 211, 10.1155/1999/168023 · DOI
  14. Wilkinson, 1999, Rivastigmine was effective and safe in Alzheimer disease, ACP Journal Club, 131, 34, 10.7326/ACPJC-1999-131-2-034 · DOI
  15. Feldman, 2007, Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease, Journal of Neurology, Neurosurgery, and Psychiatry, 78, 1056, 10.1136/jnnp.2006.099424 · DOI
  16. Burns, 2004, Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease, International Journal of Geriatric Psychiatry, 19, 243, 10.1002/gps.1058 · DOI
  17. Farlow, 2003, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Archives of Neurology, 60, 843, 10.1001/archneur.60.6.843 · DOI
  18. Burns, 2004, Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease, International Journal of Geriatric Psychiatry, 19, 243, 10.1002/gps.1058 · DOI
  19. Corey-Bloom, 1998, A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease, International Journal of Geriatric Psychopharmacology, 1, 55
  20. Doraiswamy, 2000, Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately-severe to severe AD, Clinical Neuropschological Assessment, 1, 12
  21. Doraiswamy, 2000, Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine, Clinical Neuropschological Assessment, 1, 14
  22. Farlow M Hake A Messina J Veach J Anand R The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression Neurology 2000 A469 · DOI
  23. Farlow, 2003, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Archives of Neurology, 60, 843, 10.1001/archneur.60.6.843 · DOI
  24. Farlow, 2001, Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression, Archives of Neurology, 58, 417, 10.1001/archneur.58.3.417 · DOI
  25. Krishnan, 1999, Rivastigmine slows stage specific global deterioration in Alzheimer's disease, Journal of the American Geriatrics Society, 47, S3
  26. Kumar, 2000, An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors, European Journal of Neurology, 7, 159, 10.1046/j.1468-1331.2000.00046.x · DOI · Paper page
  27. Ballard, 2005, Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial, BMJ, 330, 874, 10.1136/bmj.38369.459988.8F · DOI · Paper page
  28. Alva G Grossberg G Schmitt F Olin J Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability Annals of Neurology 2009 S49
  29. Alva G Grossberg GT Schmitt FA Meng X Olin JT Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses International Journal of Geriatric Psychiatry 2011 356 63 · DOI
  30. Blesa, 2007, Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease, Neurology, 69, S23, 10.1212/01.wnl.0000281848.25142.11 · DOI
  31. Cummings, 2007, A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia, Expert Review on Neurotherapeutics, 7, 1457, 10.1586/14737175.7.11.1457 · DOI
  32. Cummings JL Farlow MR Meng X Tekin S Olin JT Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease Clinical Drug Investigation 2010 41 9 · DOI
  33. Cummings JL Ferris SH Farlow MR Olin JT Meng XY Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis Dementia and Geriatric Cognitive Disorders 2010 406 12 · DOI
  34. Farlow M Cummings J Olin J Conference publication American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication 2009 A58 9 · DOI
  35. Farlow MR Grossberg GT Meng X Olin J Somogyi M Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy International Journal of Geriatric Psychiatry 2011 1236 43 · DOI
  36. Grossberg GT Olin JT Somogyi M Meng X Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease International Journal of Clinical Practice 2011 465 71 · DOI
  37. Grossberg GT Schmitt FA Meng X Tekin S Olin J Reviews: effects of transdermal rivastigmine on ADAS-Cog items in mild-to-moderate Alzheimers disease American Journal of Alzheimer's Disease and Other Dementias 2010 627 33 · DOI
  38. Lee JH Sevigny J Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease Alzheimer Disease and Associated Disorders 2011 58 62 · DOI
  39. Orgogozo J-M Clinical studies investigating dose-related outcomes of cholinesterase inhibition with rivastigmine patch European Journal of Neurology 2012
  40. Winblad, 2007, A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule, International Journal of Geriatric Psychiatry, 22, 456, 10.1002/gps.1788 · DOI · Paper page
  41. Winblad, 2007, IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer's disease, Neurology, 69, S14, 10.1212/01.wnl.0000281847.17519.e0 · DOI · Paper page
  42. Winblad, 2007, Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease, International Journal of Geriatric Psychiatry, 22, 485, 10.1002/gps.1806 · DOI
  43. Karaman, 2005, A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease, Dementia and Geriatric Cognitive Disorders, 19, 51, 10.1159/000080972 · DOI
  44. Nakamura Y Imai Y Shigeta M Graf A Shirahase T Kim H A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease Dementia and Geriatric Cognitive Disorders Extra 2011 163 79 · DOI
  45. Tai, 2000, The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26-week study in Taiwan, International Journal of Neuropsychopharmacology, 3 Suppl 1, S356
  46. Alva, 2013, Infrequent skin reactions at the application site of the rivastigmine patch (4.6, 9.5 or 13.3 mg/24 h): Analysis of two clinical studies revealed most were tolerable and manageable across all doses, Alzheimer's & Dementia, Conference: Alz, P666, 10.1016/j.jalz.2013.05.1373 · DOI
  47. Farlow, 2013, Long-term safety and efficacy of 13.3 mg/24 h rivastigmine patch in severe Alzheimer's disease: ACTivities of daily living and cognitION (ACTION) study, Journal of the Neurological Sciences, Conference: 21s, e339, 10.1016/j.jns.2013.07.1252 · DOI
  48. Farlow, 2013, A 24-week, open-label extension to the activities of daily living and cognition (ACTION) study: Long-term safety, tolerability and efficacy of a 13.3 mg/24h rivastigmine patch in people with severe Alzheimer's disease, Alzheimer's & Dementia, Conference: Alz, P655, 10.1016/j.jalz.2013.05.1344 · DOI
  49. Farlow, 2013, Long-term safety, tolerability and efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease, Clinical Pharmacology in Drug Development, Conference: 201, 43
  50. Farlow, 2013, Efficacy, safety and tolerability of rivastigmine patch 13.3 mg/24 h (15 cm2) versus 4.6 mg/24 h (5 cm2) in patients with severe Alzheimer's disease: Results of the activities of daily living and cognition (ACTION) study, American journal of geriatric psychiatry, Conference: 201, S139, 10.1016/j.jagp.2012.12.185 · DOI
  51. Farlow, 2014, Predictors of response to 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease, Neurology, 10.1212/WNL.82.10_supplement.P1.007 · DOI
  52. Farlow MR Doraiswamy PM Meng X Cooke K Somogyi M The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease Dementia and Geriatric Cognitive Disorders Extra 2011 150 62 · DOI
  53. Farlow, 2013, Efficacy of 13.3 mg/24 h rivastigmine patch on global functioning and behavior in severe Alzheimer's disease, Annals of neurology, Conference: 138, S91
  54. Farlow MR Grossberg G Gauthier S Meng X Olin JT The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease Current Medical Research and Opinion 2010 2441 7 · DOI
  55. Farlow, 2013, A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia, CNS Neuroscience & Therapeutics, 19, 745, 10.1111/cns.12158 · DOI
  56. Farlow, 2015, Evaluating response to high-dose 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease, CNS Neuroscience & Therapeutics, No pagination s
  57. Ferris, 2014, Cognitive efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch in severe Alzheimer's disease: Severe impairment battery factor analysis, Neurology, 10.1212/WNL.82.10_supplement.P1.009 · DOI
  58. Grossberg, 2013, Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate alzheimer's disease, American Journal of Alzheimer's Disease and Other Dementias, 28, 583, 10.1177/1533317513495104 · DOI
  59. Grossberg, 2013, Efficacy and safety of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer's disease with and without concomitant memantine use, Journal of the Neurological Sciences, Conference: 21s, e336, 10.1016/j.jns.2013.07.1244 · DOI
  60. Grossberg, 2013, Efficacy, safety and tolerability of 13.3 mg/24 h rivastigmine patch in patients with severe alzheimer's disease with and without concomitant memantine, Clinical Pharmacology in Drug Development, Conference: 201, 42
  61. Grossberg, 2013, Efficacy, safety and tolerability of a higher-dose 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease with and without concomitant memantine use, Alzheimer's & Dementia, Conference: Alz, P656, 10.1016/j.jalz.2013.05.1347 · DOI
  62. Micca, 2014, Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer's disease: A factor analysis, Neurology, 10.1212/WNL.82.10_supplement.P1.008 · DOI
  63. Sadowsky, 2013, Effect of body mass index on the efficacy, safety and tolerability of a higher-dose 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease, Alzheimer's & Dementia, Conference: Alz, P654, 10.1016/j.jalz.2013.05.1342 · DOI
  64. Sadowsky, 2011, Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis, Primary Care Companion to CNS Disorders, 13(3)
  65. Almkvist, 2004, Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients, European Journal of Neurology, 11, 253, 10.1046/j.1468-1331.2003.00757.x · DOI
  66. Auriacombe, 2003, No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment, Current Medical Research and Opinion, 19, 715, 10.1185/030079903125002504 · DOI
  67. Auriacombe, 2002, Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil, Current Medical Research and Opinion, 18, 129, 10.1185/030079902125000471 · DOI
  68. Anand, 1996, Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview, Journal of Drug Development and Clinical Practice, 8, 109
  69. Cutler, 1995, Safety and tolerance of ENA 713 in patients with Alzheimer's disease, Biological Psychiatry, 37, 643
  70. Sramek, 1996, Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease, Life Sciences, 58, 1201, 10.1016/0024-3205(96)00081-1 · DOI
  71. Bilikiewicz, 2002, An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting, Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 8, PI9
  72. Blesa Gonzalez R Boada Rovira M Martinez Parra C Gil-Saladie D Almagro CA Gobartt Vazquez AL Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease Neurologia 2011 262 71 · DOI
  73. Brassen, 2003, Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial, Pharmacopsychiatry, 36, 304, 10.1055/s-2003-45118 · DOI
  74. Caffarra, 2007, Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors, Acta Biomedica, 78, 16
  75. Aupperle, 2004, Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study, Current Medical Research and Opinion, 20, 1605, 10.1185/030079904125004204 · DOI
  76. Cummings, 2000, Abstract S79.002, Neurology, 54, A468
  77. Cutler, 1998, Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease, Acta Neurologica Scandinavica, 97, 244, 10.1111/j.1600-0404.1998.tb00645.x · DOI
  78. Cutler, 2000, Pharmacokinetics of rivastigmine and its metabolite in patients with Alzheimer's disease, Biological Psychiatry, 47 Suppl 1, S161
  79. Hossain, 2002, Non-blinded bioavailability study of oral and intravenous rivastigmine, Clinical Pharmacokinetics, 41, 225, 10.2165/00003088-200241030-00006 · DOI
  80. Dantoine, 2006, Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment, International Journal of Clinical Practice, 60, 110, 10.1111/j.1368-5031.2005.00769.x · DOI
  81. Anon Double-blind trial will compare two anti-Alzheimer's drugs Journal of Dementia Care 6
  82. Blesa, 2006, Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease, Pharmacogenetic Genomics, 16, 771, 10.1097/01.fpc.0000220573.05714.ac · DOI
  83. Bullock, 2006, Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease, Current Medical Research and Opinion, 22, 483, 10.1185/030079906X89685 · DOI
  84. Bullock, 2005, Rivastigmine and donepezil treatment in moderate to moderately severe Alzheimer's disease over a 2-year period, Current Medical Research and Opinion, 21, 1317, 10.1185/030079905X56565 · DOI · Paper page
  85. Bullock, 2005, Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period, Current Medical Research and Opinion, 21, 1317, 10.1185/030079905X56565 · DOI · Paper page
  86. Bullock, 2002, Rationale and design of EXCEED, a 24-month, double-blind study comparing rivastigmine and donepezil, Annals of Neurology, 52, 30
  87. Touchon, 2006, Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology, Current Medical Research and Opinion, 22, 49, 10.1185/030079906X80279 · DOI
  88. Frankfort, 2007, Identification of responders and reactive domains to rivastigmine in Alzheimer's disease, Pharmacoepidemiology and Drug Safety, 16, 545, 10.1002/pds.1345 · DOI
  89. Fuschillo, 2001, Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents, Archives of Gerontology and Geriatrics, 33 Suppl 1, 151, 10.1016/S0167-4943(01)00134-0 · DOI
  90. Holmes, 2007, Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study, International Journal of Geriatric Psychiatry, 22, 380, 10.1002/gps.1667 · DOI
  91. Feldman, 2004, Behavioural symptoms in mild cognitive impairment, Neurology, 62, 1199, 10.1212/01.WNL.0000118301.92105.EE · DOI · Paper page
  92. Malsch, 2001, [Treatment of Alzheimer's disease: Tolerability of rivastigmine during the initial period], Psychopharmacology, 27, 337
  93. McMillan H Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks [letter] International Journal of Geriatric Psychiatry 1999 1078 9 · DOI
  94. Alva, 2014, Efficacy of higher-dose 13.3 mg/24 h (15cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis, International Journal of Geriatric Psychiatry, 29, 920, 10.1002/gps.4080 · DOI
  95. Black S Bakchine S Bellelli G Molinuevo JL Downs P Caputo A Efficacy of the 13.3 MG/24 h rivastigmine patchoninstrumentalactivitiesofdaily living in the optimising transdermal exelon in mild-to-moderate Alzheimer's disease (optima) study: Prospective subgroup analysis by disease severity and time-to-meet decline Alzheimer's and Dementia 2012 · DOI
  96. Blesa R Martinez-Lage P Monsch AU Downs P Strohmaier C Caregiver preference for rivastigmine patch in the OPtimising Transdermal exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) Study European Journal of Neurology 2012
  97. Cummings, 2013, The rivastigmine high-dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the optimising transdermal exelon in mild-to-moderate Alzheimer's disease (OPTIMA) study, Alzheimer's & Dementia, Conference: Alz, P658, 10.1016/j.jalz.2013.05.1352 · DOI
  98. Cummings J Froelich L Black SE Bakchine S Bellelli G Molinuevo J Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm) in Alzheimer's disease Dementia and Geriatric Cognitive Disorders 2012 341 53 · DOI
  99. Cummings J Froelich L Black SE Bakchine S Bellelli G Molinuevo JL Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer's disease Dementia & Geriatric Cognitive Disorders 2012 341 53 · DOI
  100. Cummings, 2012, Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer's disease, Dementia and Geriatric Cognitive Disorders, 33, 341, 10.1159/000340056 · DOI
  101. Cummings J Frolich L Black S Bakchine S Bellelli G Molinuevo J Managing functional and cognitive decline in patients with mild-to-moderate Alzheimer's disease: a 48-week, randomized, double-blind evaluation of 13.3 mg/24 h (15 cm2) versus 9.5 mg/24 H (10 cm2) rivastigmine patch Neurology 2012 · DOI
  102. Cummings J Grossberg G Alva G Caputo A Downs P Strohmaier C High-dose 13.3 MG/24 h rivastigmine transdermal patch demonstrates efficacy on instrumental activities of daily living: Individual item analysis Alzheimer's and Dementia 2012 · DOI
  103. Frampton, 2014, Rivastigmine transdermal patch 13.3 mg/24 h: a review of Its use in the management of mild to moderate Alzheimer's dementia, Drugs & Aging, 31, 639, 10.1007/s40266-014-0197-x · DOI
  104. Frolich L High-dose rivastigmine patch: Results from the optima study Neurobiology of Aging 2012 · DOI
  105. Frolich L Monsch A Kressig R Downs P Caputo A Strohmaier C Comparisons of patient characteristics in subpopulations of the optimising transdermal Exelon in mild-to-moderate Alzheimer's disease (OPTIMA) study Alzheimer's and Dementia 2012 · DOI
  106. Frolich L Touchon J Massaia M Callegari F Strohmaier C Safety and tolerability of 9.5mg/24h(10cm2) and 13.3mg/24h (15cm2) rivastigmine patches: results from the optimising transdermal Exelon in mild-to-moderate Alzheimer's disease (OPTIMA) study European Journal of Neurology 2012
  107. Molinuevo, 2013, High-dose 13.3 mg/24 h rivastigmine patch efficacy and safety in mild-to-moderate Alzheimer's disease with and without concomitant memantine use, Journal of the Neurological Sciences, Conference: 21s, e348, 10.1016/j.jns.2013.07.1280 · DOI
  108. Molinuevo, 2013, Incidence and predictors of response to the 13.3 (15 cm2) and 9.5 mg/24h (10 cm2) rivastigmine patch in the optimising transdermal Exelon in mild-to-moderate Alzheimer's disease (OPTIMA) study, Alzheimer's & Dementia, Conference: Alz, P656, 10.1016/j.jalz.2013.05.1349 · DOI
  109. Molinuevo, 2013, Predictors of response to the 13.3 and 9.5 mg/24 h rivastigmine patch: The optimizing transdermal Exelon in mild-to-moderate Alzheimer's disease (optima) study, Journal of the neurological sciences, Conference: 21s, e336, 10.1016/j.jns.2013.07.1243 · DOI
  110. Sadowsky, 2013, Effect of body mass index on the efficacy, safety and tolerability of higher-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer's disease, Clinical Pharmacology in Drug Development, Conference: 201, 42
  111. Potkin, 2001, Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease, International Journal of Neuropsychopharmacology, 4, 223, 10.1017/S1461145701002528 · DOI · Paper page
  112. Schmidt, 2002, Rivastigmine in outpatient services: experience of 114 neurologists in Austria, International Clinical Psychopharmacology, 17, 81, 10.1097/00004850-200203000-00007 · DOI
  113. Small, 2005, Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years, International Journal of Clinical Practice, 59, 473, 10.1111/j.1368-5031.2005.00524.x · DOI
  114. Thomas, 2001, Donepezil, rivastigmine,and vitamin E in Alzheimer disease: A combined P300 event-related potentials/neuropsychologic evaluation over 6 months, Clinical Neuropharmacology, 24, 31, 10.1097/00002826-200101000-00007 · DOI
  115. Wang, 2001, The treatment by using rivastigmine for patients with alzheimer disease: results of a multicenter, randomized, open-labeled, controlled clinical trial, Chinese Journal of Neurology, 34, 210
  116. Wang, 2003, [Efficacy of rivastigmine in treating mild to severe alzheimer's disease with different hachinski ischemia index], Chinese Journal of Neurology, 36, 44
  117. Weiser, 2002, A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances, International Journal of Geriatric Psychiatry, 17, 343, 10.1002/gps.599 · DOI
  118. Bullock, 2001, The tolerability, ease of use and efficacy of donepezil and rivastigmine in Alzheimer's disease patients: a 12-week, multinational, comparative study, Journal of the American Geriatrics Society, 49, S19
  119. Wilkinson, 2002, A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease, International Journal of Clinical Practice, 56, 441, 10.1111/j.1742-1241.2002.tb11294.x · DOI · Paper page
  120. Benton, 1974, Revised visual retention test
  121. Birks, 2006, Donepezil for dementia due to Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001190.pub2 · DOI · Paper page
  122. Birks, 2008, The evidence for the efficacy of cholinesterase inhibitors in the treatment of Alzheimer's disease is convincing, International Psychogeriatrics, 20, 279, 10.1017/S1041610207006977 · DOI
  123. Brunner, 1990, Eine Validierungsstudie mit der NOSGER (Nurses' Observation Scale for Geriatric Patients), einem neuen Beurteilungsinstrument für die Psychogeriatrie, Zeitschr für Psychologie, XIX, 211
  124. Burns, 2004, Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease, International Journal of Geriatric Psychiatry, 19, 243, 10.1002/gps.1058 · DOI
  125. Clegg, 2002, Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease: a systematic review, International Journal of Technology Assessment in Health Care, 18, 497, 10.1017/S026646230200034X · DOI
  126. Cohen-Mansfield, 1995, Assessment of disruptive behaviour/agitation in the elderly: function, methods and difficulties, Journal of Geriatric Psychiatry Neurology, 8, 52
  127. DeJong, 1989, Measurement of Quality-of-Life changes in patients with Alzheimer's Disease, Clinical Therapeutics, 11, 545
  128. 1994, Diagnostic and Statistical Manual of Mental Disorders
  129. Erkinjuntti, 2002, Rivastigmine in patients with Alzheimer's disease and concurrent hypertension, International Journal of Clinical Practice, 56, 791, 10.1111/j.1742-1241.2002.tb11377.x · DOI
  130. Farlow, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Archives of Neurology, 60, 843, 10.1001/archneur.60.6.843 · DOI
  131. Fillit, 2004, The economic benefits of acetylcholinesterase inhibitors for patients with alzheimer disease and associated dementias, Alzheimer Disease and Associated Disorders, 18 Suppl 1, S24, 10.1097/01.wad.0000127492.65032.d3 · DOI
  132. Folstein, 1975, ‘Mini-Mental State’: A practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
  133. Fuld, 1981, The Fuld object memory evaluation
  134. Galasko, 1997, An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study, Alzheimer Disease and Associated Disorders, 11, 33, 10.1097/00002093-199700112-00005 · DOI · Paper page
  135. Gelinas, 1999, Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia, American Journal of Occupational Therapy, 53, 471, 10.5014/ajot.53.5.471 · DOI · Paper page
  136. Grossberg, 2000, Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications, International Journal of Geriatric Psychiatry, 15, 242, 10.1002/(SICI)1099-1166(200003)15:3<242::AID-GPS110>3.0.CO;2-7 · DOI
  137. Guy, 1976, ECDEU Assessment manual for psychopharmacology
  138. Hauber, 2000, Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine, Clinical Therapeutics, 22, 439, 10.1016/S0149-2918(00)89012-8 · DOI
  139. Homma, 1991, Development of a new rating scale for dementia in the elderly: Mental Function Impairment Scale (MENFIS), Japanese Journal of Geriatric Psychiatry, 2, 1217
  140. Howard, 2011, Determining the minimum clinically important differences for outcomes in the DOMINO trial, International Journal of Geriatric Psychiatry, 26, 812, 10.1002/gps.2607 · DOI · Paper page
  141. Jann, 2000, Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease, Pharmacotherapy, 20, 1, 10.1592/phco.20.1.1.34664 · DOI · Paper page
  142. Kennedy, 1999, Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans, Journal of Clinical Psychopharmacology, 19, 513, 10.1097/00004714-199912000-00005 · DOI
  143. McKhann, 1984, Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  144. Panisset, 1994, Severe impairment battery: a neurological test for severely demented patients, Archives of Neurology, 51, 41, 10.1001/archneur.1994.00540130067012 · DOI · Paper page
  145. Polinsky, 1998, Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, Clinical Therapeutics, 20, 634, 10.1016/S0149-2918(98)80127-6 · DOI · Paper page
  146. Reisberg, 1982, The global deterioration scale for assessment of primary degenerative dementia, American Journal of Psychiatry, 139, 1136, 10.1176/ajp.139.9.1136 · DOI · Paper page
  147. Reisberg, 1989, Stage specific incidence of potentially remediable behavioral symptoms in aging and AD: a study of 120 patients using the BEHAVE-AD, Bulletin of Clinical Neuroscience, 54, 95
  148. Reisberg, 1994, CIBIC-plus interview guide
  149. Reitan, 1958, The validity of the Trail Making Test as an indicator of organic brain damage, Perceptual and Motor Skills, 8, 271, 10.2466/pms.1958.8.3.271 · DOI · Paper page
  150. Rosen, 1984, A new rating scale for Alzheimer’s disease, American Journal of Psychiatry, 41, 356
  151. Saxton, 1990, Assessment of severely impaired patients: description and validation of a new neuropsychological test battery, Psychological Assessment, 2, 298, 10.1037/1040-3590.2.3.298 · doi:10.1037/1040-3590.2.3.298 · Paper page
  152. Schneider, 1997, Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study, Alzheimer Disease and Associated Disorders, 11 Suppl 2, S22, 10.1097/00002093-199700112-00004 · DOI · Paper page
  153. Schneider, 1998, Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease, International Journal of Geriatric Psychopharmacology, 1, S26
  154. Schrag, 2012, Research paper: What is the clinically relevant change on the ADAS-Cog?, Journal of Neurology, Neurosurgery, and Psychiatry, 83, 171, 10.1136/jnnp-2011-300881 · DOI
  155. Spencer, 1998, Rivastigmine. A review of its use in Alzheimer's disease, Drugs & Aging, 13, 391, 10.2165/00002512-199813050-00005 · DOI · Paper page
  156. Watson, 1993, Clock completion: an objective screening test for dementia, Journal of the American Geriatric Society, 41, 1235, 10.1111/j.1532-5415.1993.tb07308.x · DOI · Paper page
  157. Wechsler, 1987, Wechsler Memory Scale-Revised (WMS-R)
  158. Williams, 2003, A review of rivastigmine: a reversible cholinesterase inhibitor, Clinical Therapeutics, 25, 1634, 10.1016/S0149-2918(03)80160-1 · DOI
  159. Birks, 2000, Rivastigmine for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001191 · DOI · Paper page

Cited by

See all 247

Metadata

Authors
Birks, J. S., & Grimley Evans, J.
Venue
Cochrane Database of Systematic Reviews
Published
2015-04-10
Issue
4
Pages
CD001191-CD001191
ISSN
1361-6137 (ISSN-L)
OpenAlex
W4211189332
Cited by
247
References
6
Type
reference entry
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rivastigmine for Alzheimer's disease. https://app.cochat.ai/papers/10.1002/14651858.cd001191.pub3
The paper
Birks, J. S., & Grimley Evans, J. (2015). Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001191.pub3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.